Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:HSAQNASDAQ:KRMDNASDAQ:NYXHNASDAQ:OBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSAQHealth Sciences Acquisitions Co. 2$4.48-0.9%$5.53$9.41▼$13.80$50.23M0.09205,918 shs24,426 shsKRMDKORU Medical Systems$2.19-0.5%$2.18$1.98▼$4.48$100.11M0.5394,698 shs50,648 shsNYXHNyxoah$11.29+6.4%$13.53$4.00▼$20.00N/A1.555,711 shs22,016 shsOBIOOrchestra BioMed$4.44-0.9%$5.51$4.22▼$20.19$158.86M0.1549,178 shs55,556 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSAQHealth Sciences Acquisitions Co. 2-0.88%-3.03%-10.40%-47.85%-69.95%KRMDKORU Medical Systems+2.80%+3.77%0.00%+3.77%-45.54%NYXHNyxoah+2.10%+12.04%-21.09%+42.57%+19.82%OBIOOrchestra BioMed-0.88%-3.03%-10.40%-44.07%-68.91%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/AKRMDKORU Medical Systems1.6221 of 5 stars3.51.00.00.01.52.50.6NYXHNyxoah1.5922 of 5 stars4.42.00.00.00.60.80.0OBIOOrchestra BioMed0.7042 of 5 stars3.52.00.00.00.00.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AKRMDKORU Medical Systems3.00Buy$3.5059.82% UpsideNYXHNyxoah2.83Moderate Buy$20.6082.46% UpsideOBIOOrchestra BioMed3.00Buy$17.00282.88% UpsideCurrent Analyst RatingsLatest HSAQ, NYXH, OBIO, and KRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/20/2024NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $22.003/20/2024NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $27.003/14/2024KRMDKORU Medical SystemsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/14/2024NYXHNyxoahOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $20.003/6/2024NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.003/6/2024NYXHNyxoahPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$15.00 ➝ $20.003/5/2024NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.002/28/2024NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $18.002/9/2024NYXHNyxoahCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $14.002/1/2024NYXHNyxoahPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $15.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/AKRMDKORU Medical Systems$28.52M3.51N/AN/A$0.45 per share4.87NYXHNyxoah$4.70MN/AN/AN/A$5.08 per shareN/AOBIOOrchestra BioMed$2.76M57.56N/AN/A$1.90 per share2.34Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/AKRMDKORU Medical Systems-$13.74M-$0.29N/AN/AN/A-48.18%-27.82%-21.30%5/1/2024 (Confirmed)NYXHNyxoah-$46.77M-$1.68N/AN/AN/A-993.28%-38.58%-31.24%5/21/2024 (Estimated)OBIOOrchestra BioMed-$49.12M-$1.50N/AN/AN/A-1,779.71%-58.32%-41.47%5/10/2024 (Estimated)Latest HSAQ, NYXH, OBIO, and KRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AKRMDKORU Medical Systems-$0.04N/A+$0.04N/AN/AN/A 3/27/2024Q4 2023OBIOOrchestra BioMed-$0.38-$0.37+$0.01-$0.37$1.00 million$0.26 million3/13/2024Q4 2023KRMDKORU Medical Systems-$0.04-$0.02+$0.02$0.12$7.01 million$7.19 million3/5/2024Q4 2023NYXHNyxoah-$0.41-$0.41N/A-$0.41$2.01 million$1.96 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSAQHealth Sciences Acquisitions Co. 2N/A0.170.61KRMDKORU Medical Systems0.024.553.77NYXHNyxoah0.124.734.50OBIOOrchestra BioMedN/A7.957.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSAQHealth Sciences Acquisitions Co. 289.71%KRMDKORU Medical Systems58.60%NYXHNyxoahN/AOBIOOrchestra BioMed53.55%Insider OwnershipCompanyInsider OwnershipHSAQHealth Sciences Acquisitions Co. 221.90%KRMDKORU Medical Systems25.60%NYXHNyxoah17.11%OBIOOrchestra BioMedN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableKRMDKORU Medical Systems8245.71 million34.01 millionOptionableNYXHNyxoah137N/AN/ANot OptionableOBIOOrchestra BioMed5635.78 millionN/ANot OptionableHSAQ, NYXH, OBIO, and KRMD HeadlinesSourceHeadlineReviewing Orchestra BioMed (OBIO) & The Competitionamericanbankingnews.com - April 24 at 1:16 AMCritical Review: Orchestra BioMed (OBIO) & Its Peersamericanbankingnews.com - April 20 at 1:40 AMComparing Orchestra BioMed (OBIO) and Its Peersamericanbankingnews.com - April 15 at 1:50 AMOrchestra BioMed: Continuing the Momentum into a Promising Futuremsn.com - March 31 at 11:03 PMOrchestra BioMed Bolsters Board with Healthcare Industry Veteran David Pacittimsn.com - March 31 at 12:42 PMOrchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 29 at 8:20 AMOrchestra BioMed's (OBIO) Buy Rating Reaffirmed at Chardan Capitalmarketbeat.com - March 28 at 9:24 AMBuy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Datamarkets.businessinsider.com - March 28 at 2:13 AMOBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 27 at 11:03 PMOrchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Updateglobenewswire.com - March 27 at 4:17 PMOrchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directorsglobenewswire.com - March 26 at 8:00 AMOrchestra BioMed's AVIM Therapy Demonstrates Promising Results in Controlling Hypertensionmsn.com - March 11 at 8:00 AMOrchestra BioMed to Participate in Upcoming Investor Conferencesglobenewswire.com - March 7 at 8:00 AMOrchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patientsglobenewswire.com - March 6 at 8:37 AMWhy Orchestra BioMed (OBIO) Might Surprise This Earnings Seasonfinance.yahoo.com - February 16 at 2:24 PMWhy Orchestra BioMed (OBIO) Might Surprise This Earnings Seasonzacks.com - February 16 at 10:16 AMOrchestra BioMed Hldgs Stock (NASDAQ:OBIO), Short Interest Reportbenzinga.com - January 19 at 9:01 PMJefferies starts Orchestra BioMed at buy, cites lead program opportunitiesmsn.com - January 19 at 9:01 PMOrchestra BioMed Holdings Inc OBIOmorningstar.com - January 16 at 10:41 AMOrchestra BioMed begins pivotal trial of cardiac neuromod techmassdevice.com - January 8 at 6:55 PMSilicon Box Accelerates Industry Leadership With Production Commencement at its World Leading Advanced Packaging Facility and Series B Fundraisingsg.finance.yahoo.com - January 8 at 8:54 AMOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has caught the attention of hedge funds investors who hold a sizeable 28% stakefinance.yahoo.com - January 3 at 12:03 PMBATL, SNCR and BVN are among pre market gainersmsn.com - December 18 at 11:06 AMOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 16 at 9:27 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsHealth Sciences Acquisitions Co. 2NASDAQ:HSAQHealth Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.KORU Medical SystemsNASDAQ:KRMDKORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.NyxoahNASDAQ:NYXHNyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Orchestra BioMedNASDAQ:OBIOOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.